ANTI-OBESITY DRUGS SHOULD BE FOR CHRONIC USE SIMILAR TO ANTIHYPERTENSIVES, FDA INVITED GUESTS CONTEND; PROPOSED GUIDANCE WOULD BE BARRIER TO DRUG R&D
Executive Summary
Anti-obesity drugs must be used on a chronic basis for continued efficacy, Pennington Biomedical Research Center Executive Director George Bray, MD, maintained at FDA's Endocrinologic & Metabolic Drugs Advisory Committee meeting on Jan. 19.